6.18
0.40%
-0.025
Handel nachbörslich:
6.18
Schlusskurs vom Vortag:
$6.205
Offen:
$6.26
24-Stunden-Volumen:
851.55K
Relative Volume:
1.30
Marktkapitalisierung:
$295.87M
Einnahmen:
$15.84M
Nettoeinkommen (Verlust:
$-308.48M
KGV:
-1.5685
EPS:
-3.94
Netto-Cashflow:
$-153.08M
1W Leistung:
-19.32%
1M Leistung:
-3.74%
6M Leistung:
+23.35%
1J Leistung:
-10.30%
Uniqure N V Stock (QURE) Company Profile
Firmenname
Uniqure N V
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Vergleichen Sie QURE mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
QURE | 6.18 | 295.87M | 15.84M | -308.48M | -153.08M | -3.94 |
VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2022-03-17 | Hochstufung | UBS | Neutral → Buy |
2021-06-15 | Eingeleitet | BTIG Research | Buy |
2021-05-21 | Eingeleitet | UBS | Neutral |
2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
2020-11-11 | Eingeleitet | Berenberg | Buy |
2020-11-09 | Eingeleitet | Jefferies | Buy |
2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2019-12-03 | Eingeleitet | Cowen | Outperform |
2019-12-03 | Eingeleitet | Goldman | Buy |
2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
2019-10-11 | Eingeleitet | Stifel | Buy |
2019-09-25 | Eingeleitet | Bernstein | Outperform |
2019-09-12 | Eingeleitet | Mizuho | Buy |
2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure N V Aktie (QURE) Neueste Nachrichten
(QURE) Investment Analysis - Stock Traders Daily
uniQure NV (LTS:0EE0) Enterprise Value : $-65.19 Mil (As of Nov. 16, 2024) - GuruFocus.com
uniQure FY2024 EPS Estimate Reduced by Cantor Fitzgerald - MarketBeat
Privium Fund Management B.V. Acquires 104,500 Shares of uniQure (NASDAQ:QURE) - MarketBeat
Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade - Yahoo Finance
(QURE) On The My Stocks Page - Stock Traders Daily
uniQure FY2024 EPS Estimate Boosted by Leerink Partnrs - MarketBeat
HC Wainwright Issues Positive Estimate for uniQure Earnings - MarketBeat
William Blair Issues Positive Estimate for uniQure Earnings - MarketBeat
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - cnhinews.com
What Does The Future Hold For uniQure N.V. (NASDAQ:QURE)? These Analysts Have Been Cutting Their Estimates - Yahoo Finance
QUREuniQure N.V. Latest Stock News & Market Updates - StockTitan
Cantor Fitzgerald Reaffirms "Overweight" Rating for uniQure (NASDAQ:QURE) - MarketBeat
uniQure Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
uniQure N.V. Reports Q3 2024 Progress and Financials - TipRanks
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewswire
Uniqure NV earnings beat by $0.11, revenue fell short of estimates - Investing.com Australia
UniQure: Q3 Earnings Snapshot - San Francisco Chronicle
uniQure NV Q3 2024 Earnings: EPS Loss of $0.91 Beats Estimates, Revenue of $2.3 Million Misses Expectations - GuruFocus.com
uniQure reports Q3 EPS (91c), consensus ($1.01) - TipRanks
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
uniQure's Breakthrough: Huntington's Trial Success, $435M Cash Runway Through 2027 | QURE Stock News - StockTitan
abrdn plc Buys 1,528,581 Shares of uniQure (NASDAQ:QURE) - MarketBeat
Assenagon Asset Management S.A. Has $1.34 Million Stake in uniQure (NASDAQ:QURE) - MarketBeat
Multiple Insiders Sold uniQure Shares Presenting Weak Signs For Investors - Simply Wall St
UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
uniQure (NASDAQ:QURE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Pfizer Loses Hemophilia Gene Therapy Patent Row To UniQure - Law360
uniQure’s Yellow Flags: Early-Stage Gene Therapies Amid Restructuring - Seeking Alpha
State Street Corp's Strategic Reduction in uniQure NV Holdings - GuruFocus.com
How To Trade (QURE) - Stock Traders Daily
uniQure (NASDAQ:QURE) Upgraded to Sell by StockNews.com - MarketBeat
uniQure (NASDAQ:QURE) Upgraded by StockNews.com to “Sell” - Defense World
uniQure N.V. (QURE) requires closer examination - US Post News
uniQure Initiates Trial for Promising ALS Gene Therapy - TipRanks
uniQure announces dosing of first patient in Phase I/II trial of AMT-162 - TipRanks
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS - GlobeNewswire
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS - StockTitan
Raymond James gives an Outperform recommendation for uniQure N.V. (QURE) - Knox Daily
Ratios Uncovered: Breaking Down uniQure N.V. (QURE)’s Trailing Twelve Months Metrics - The Dwinnex
Marshall Wace LLP Invests $175,000 in uniQure (NASDAQ:QURE) - Defense World
uniQure shares coverage resumed on robust clinical portfolio - Investing.com
Raymond James Reiterates Outperform Rating for uniQure (NASDAQ:QURE) - MarketBeat
uniQure shares coverage resumed on robust clinical portfolio By Investing.com - Investing.com UK
A company insider recently sold 1,447 shares of uniQure N.V. [QURE]. Should You Sale? - Knox Daily
An analyst sees good growth prospects for uniQure N.V. (QURE) - SETE News
Market Recap: uniQure N.V. (QURE)’s Positive Momentum, Closing at 5.92 - The Dwinnex
The uniQure N.V. (QURE) had a good session last reading, didn’t it? - US Post News
uniQure N.V.’s Mixed Bag: Up 9.71% in 6 Months, Up 2.17% in 30 Days - The InvestChronicle
uniQure (NASDAQ:QURE shareholders incur further losses as stock declines 10% this week, taking five-year losses to 89% - Simply Wall St
Technical analysis of uniQure N.V. (QURE) stock chart patterns - US Post News
Finanzdaten der Uniqure N V-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):